Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Completed · Phase 4 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy

Key facts

Study ID

NCT02412644

Run by

Psoriasis Treatment Center of Central New Jersey

People needed

29

Starts

2015-05-28

Expected to finish

2016-07-01

Last updated by the study team

2019-01-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Subjects who meet any of the following criteria will be excluded from participation in this study:
• Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis
• Subjects with previous exposure to apremilast
• Malignancy or history of malignancy, except for:
• treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;
• treated [ie, cured] malignancy with no evidence of recurrence within the previous 5 years.

Where it is running

• Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.